143 related articles for article (PubMed ID: 22045672)
1. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
[TBL] [Abstract][Full Text] [Related]
2. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
3. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
4. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
5. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
[TBL] [Abstract][Full Text] [Related]
6. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
7. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
Bruno S; Stroffolini T; Colombo M; Bollani S; Benvegnù L; Mazzella G; Ascione A; Santantonio T; Piccinino F; Andreone P; Mangia A; Gaeta GB; Persico M; Fagiuoli S; Almasio PL;
Hepatology; 2007 Mar; 45(3):579-87. PubMed ID: 17326216
[TBL] [Abstract][Full Text] [Related]
9. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
10. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
Singal AG; Volk ML; Jensen D; Di Bisceglie AM; Schoenfeld PS
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):280-8, 288.e1. PubMed ID: 19948249
[TBL] [Abstract][Full Text] [Related]
11. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
[TBL] [Abstract][Full Text] [Related]
12. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
13. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
[TBL] [Abstract][Full Text] [Related]
14. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
Imazeki F; Yokosuka O; Fukai K; Saisho H
Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
[TBL] [Abstract][Full Text] [Related]
15. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H; McDonald S; Hayes P; Dillon JF; Allen S; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley A; Bramley P; Hutchinson SJ
J Hepatol; 2017 Jan; 66(1):19-27. PubMed ID: 27545496
[TBL] [Abstract][Full Text] [Related]
16. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
17. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
18. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
[TBL] [Abstract][Full Text] [Related]
19. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
20. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
